< Back to topics
> Cover Page, Authors, Institutions
> View tables/images/videos
To report results of a phase I study
of highly individualized, hypofractionated SRT in unresectable CC and HCC.
Patients with unresectable hepatocellular carcinoma (HCC) and intrahepatic
cholangiocarcinoma (CC) have few treatment options and a poor prognosis. Highly
individualized, hypofractionated stereotactic radiotherapy (SRT) is a novel
treatment with the potential to improve outcomes in HCC and CC.